January 12, 2012 -- Amerigen Pharma announced two new cross-border relationships in quick succession. The agreements move the company toward its goals of developing a large portfolio of differentiated generic drugs for sale in the US and China. With Shanghai Fosun Omni Pharma, Amerigen will develop controlled release oral generic products, which Amerigen will commercialize in the US. Amerigen also signed an MOU with VIWA Pharma, a China company, to set up a JV that will develop and register a number of branded generics for sale in China. More details....
